Drug
Sacituzumab Govitecan
Drug Profile
| Therapeutic Class | Antibody-Drug Conjugates (ADCs) |
| Drug Class | — |
| Group | ADC |
| Mechanism of Action | Trop-2 targeting ADC |
| Half-life | ADC t½ 6.5–6.7 d; free SN-38 payload 22–24 h |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing mechanistically (SN-38 topo I DNA breaks, overcomes RAD51/HR), though topo I payload sensitization was less consistent than MMAE (Lesperance et al., Advanced Science, 2026; Tolaney et al., Clinical Cancer Research, 2025). Because free SN-38 is a classic chemoradiosensitizer, a theoretical increase in in-field GI/mucosal adverse events and additive neutropenia/diarrhea is plausible.
Data on this page refer exclusively to patients treated with
Sacituzumab Govitecan combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
ADC group page.